Teva must face US antitrust claims over asthma inhalers, judge rules
MLex Summary: Teva Pharmaceuticals must face US claims accusing it of improperly delaying generic entry by implementing an anticompetitive scheme focused on enforcing its patents covering QVAR, a US judge ruled....To view the full article, register now.
Already a subscriber? Click here to view full article